

[318] PREDICTIVE CRITICAL CARE

Gal Salomon¹, Izik Itzhakov¹, ¹ Intensix

Questions for Biotech/Pharma; Medical Devices and Health IT/Digital Health categories are:

- **Investment Rational**
Intensix is an analytics platform that predicts patient deterioration, in real-time, by identifying patterns in physiological data. By leveraging high volume and high velocity analytics, we enable the early detection of life-threatening complications, improving the patient's clinical outcomes and reducing the cost of treatment.
- **Business Strategy**
Following three successful retrospective studies, the Intensix platform is now running live at TASMIC (Ichilov), in Israel, and at Mayo Clinic, in the U.S., for proof of concept trials. Later in 2017, the company is planning on opening its U.S. headquarters in Boston to locally support installations of its prediction platform.
- **Core Technology**
Intensix applies machine learning on big data and analyzes high resolution data coming from sources inside critical care units to provide real-time predictions of patient deteriorations before they occur. We enable physicians to better understand, manage and improve patient outcomes.
- **Product Profile/Pipeline**
The initial phase of developing the infrastructure and platform is complete. Currently, the company is focused on refining prediction models and the UI. We are in ongoing discussions with various hospitals. Most of these facilities are tier 1 medical centers. The company's goal is to be up and running in 3 centers in the US by year end 2017

What's Next?

Following a successful Series A fund, the plan for the next 24 months is to increase development capacity, build a commercialized product, support 4 ongoing studies in the US, establish a marketing and sales force in the US and refine a reproducible implementation methodology.